HuGE Literature Finder
Records
1
-
27
| The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients. Pharmacogenomics and personalized medicine 2022 15 817-825. He Jia, Wang Zhan, Zou Ting, Wang Ying, Li Xiang-Ping, Chen Ju |
| ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. Investigational new drugs 2020 May . Sakamoto Sho, Sato Kazuhiro, Takita Yuri, Izumiya Yuka, Kumagai Naho, Sudo Kazuhisa, Hasegawa Yukiyasu, Yokota Hayato, Akamine Yumiko, Okuda Yuji, Asano Mariko, Takeda Masahide, Sano Masaaki, Miura Masatomo, Nakayama Katsutos |
| The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. Annals of translational medicine 2019 Dec 7 (24): 806. Ma Yuxiang, Xin Shuang, Lin Qingguang, Zhuang Wei, Zhao Yuanyuan, Zhu Xia, Zhao Hongyun, Huang Min, Xun Xu, Yang Yunpeng, Fang Wenfeng, Zhang Li, Wang Xuedi |
| Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. BMC cancer 2018 May 18 (1): 555. Limviphuvadh Vachiranee, Tan Chee Seng, Konishi Fumikazu, Jenjaroenpun Piroon, Xiang Joy Shengnan, Kremenska Yuliya, Mu Yar Soe, Syn Nicholas, Lee Soo Chin, Soo Ross A, Eisenhaber Frank, Maurer-Stroh Sebastian, Yong Wei Pe |
| Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis. OncoTargets and therapy 2018 11 665-675. Tang Lina, Zhang Chunling, He Hairong, Pan Zhenyu, Fan Di, He Yinli, You Haisheng, Li Yuanj |
| Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters. Biological & pharmaceutical bulletin 2018 41 (1): 47-56. Endo-Tsukude Chihiro, Sasaki Ji-Ichiro, Saeki Sho, Iwamoto Norihiro, Inaba Megumi, Ushijima Sunao, Kishi Hiroto, Fujii Shinji, Semba Hiroshi, Kashiwabara Kosuke, Tsubata Yukari, Hayashi Mitsuhiro, Kai Yuki, Saito Hideyuki, Isobe Takeshi, Kohrogi Hirotsugu, Hamada Akino |
| Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget 2017 Aug 8 (34): 57528-57536. Kim Lucia, Saieg Mauro, Di Maio Massimo, Gallo Ciro, Butts Charles, Ciardiello Fortunato, Feld Ronald, Cheng Dengxiao, Gebbia Vittorio, Burgio Marco Angelo, Alam Yasmin, Signoriello Simona, Rossi Antonio, Leighl Natasha, Maione Paolo, Morabito Alessandro, Liu Geoffrey, Tsao Ming-Sound, Perrone Francesco, Gridelli Cesa |
| Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Scientific reports 2017 Jul 7 (1): 5082. Cui Jia-Jia, Wang Lei-Yun, Zhu Tao, Gong Wei-Jing, Zhou Hong-Hao, Liu Zhao-Qian, Yin Ji- |
| A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population. The pharmacogenomics journal 2016 Mar . Sun J, Zhu M, Shen W, Wang C, Dai J, Xu L, Jin G, Hu Z, Ma H, Shen |
| Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2016 Mar 93 69-76. Hirose Takashi, Fujita Ken-Ichi, Kusumoto Sojiro, Oki Yasunari, Murata Yasunori, Sugiyama Tomohide, Ishida Hiroo, Shirai Takao, Nakashima Masanao, Yamaoka Toshimitsu, Okuda Kentaro, Ohmori Tohru, Sasaki Yasutsu |
| Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer 2015 Jul 16 (4): 274-81. Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masato |
| Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy. American journal of clinical oncology 2015 Jun 38 (3): 294-9. Kim Seok-Hyun, Kim Moon Jin, Cho Yu Ji, Jeong Yi Yeong, Kim Ho-Cheol, Lee Jong Duk, Hwang Young Sil, Kim In-Suk, Lee Suee, Oh Sung Yong, Ling Hui, Lee Gyeong-W |
| Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients. Cancer cell international 2015 15 43. Chen Xueqin, Chen Dadong, Yang Shaoyu, Ma Ruobing, Pan Yuelong, Li Xin, Ma Shengl |
| Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers. Oncology letters 2014 Jun 7 (6): 2035-2040. Moriya Hiroyuki, Saito Katsuhiko, Helsby Nuala, Sugino Shigekazu, Yamakage Michiaki, Sawaguchi Takeru, Takasaki Masahiko, Kato Hidenori, Kurosawa Naho |
| Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 2014 15 (12): 1565-74. Lamba Jatinder Kaur, Fridley Brooke L, Ghosh Taraswi M, Yu Qing, Mehta Gaurav, Gupta Pank |
| Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2013 Oct 67 (8): 801-6. Li Ning, Song Yuanyuan, Du Ping, Shen Yinchen, Yang Jianliang, Gui Lin, Wang Shuai, Wang Jianfei, Sun Yan, Han Xiaohong, Shi Yuank |
| Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clinical pharmacokinetics 2013 Jul 52 (7): 593-609. Fukudo Masahide, Ikemi Yasuaki, Togashi Yosuke, Masago Katsuhiro, Kim Young Hak, Mio Tadashi, Terada Tomohiro, Teramukai Satoshi, Mishima Michiaki, Inui Ken-Ichi, Katsura Toshi |
| A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. International journal of cancer. Journal international du cancer 2012 Dec 131 (12): 2920-8. Campa Daniele, Müller Phillip, Edler Lutz, Knoefel Lena, Barale Roberto, Heussel Claus P, Thomas Michael, Canzian Federico, Risch Ange |
| Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya journal of medical science 2012 Feb 74 (1-2): 133-40. Tamura Mariko, Kondo Masashi, Horio Mihoko, Ando Maki, Saito Hiroshi, Yamamoto Masashi, Horio Yoshitsugu, Hasegawa Yoshino |
| Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 Feb 7 (2): 316-22. Liu Geoffrey, Cheng D, Ding K, Le Maitre A, Liu N, Patel D, Chen Z, Seymour L, Shepherd F A, Tsao M |
| Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 2011 Feb 12 (2): 159-70. Lemos Clara, Giovannetti Elisa, Zucali Paolo A, Assaraf Yehuda G, Scheffer George L, van der Straaten Tahar, D'Incecco Armida, Falcone Alfredo, Guchelaar Henk-Jan, Danesi Romano, Santoro Armando, Giaccone Giuseppe, Tibaldi Carmelo, Peters Godefridus |
| Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer chemotherapy and pharmacology 2010 Sep 66 (4): 691-8. Akasaka Keiichi, Kaburagi Takayuki, Yasuda Shin'ichi, Ohmori Kyoko, Abe Kaori, Sagara Hironori, Ueda Yoshihiko, Nagao Koshu, Imura Johji, Imai Yas |
| Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. International journal of cancer. Journal international du cancer 2009 Apr 124 (7): 1669-74. Müller Phillip J, Dally Heike, Klappenecker Cornelia N, Edler Lutz, Jäger Birgit, Gerst Martina, Spiegelhalder Bertold, Tuengerthal Siegfried, Fischer Jürgen R, Drings Peter, Bartsch Helmut, Risch Ange |
| Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Mar 26 (7): 1119-27. Rudin Charles M, Liu Wanqing, Desai Apurva, Karrison Theodore, Jiang Xuemin, Janisch Linda, Das Soma, Ramirez Jacqueline, Poonkuzhali Balasubramanian, Schuetz Erin, Fackenthal Donna Lee, Chen Peixian, Armstrong Deborah K, Brahmer Julie R, Fleming Gini F, Vokes Everett E, Carducci Michael A, Ratain Mark |
| Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007 Jul 110 (1): 138-47. Han Ji-Youn, Lim Hyeong-Seok, Yoo Yeon-Kyeong, Shin Eun Soon, Park Yong Hoon, Lee Sung Young, Lee Jong-Eun, Lee Dea Ho, Kim Heung Tae, Lee Jin S |
| Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. Journal of the National Cancer Institute 2006 Dec 98 (23): 1739-42. Cusatis George, Gregorc Vanesa, Li Jing, Spreafico Anna, Ingersoll Roxann G, Verweij Jaap, Ludovini Vienna, Villa Eugenio, Hidalgo Manuel, Sparreboom Alex, Baker Sharyn |
| Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea. In vivo (Athens, Greece) 0 34 (3): 1415-1419. Sogawa Rintaro, Nakashima Chiho, Nakamura Tomomi, Takeuchi Koji, Kimura Sakiko, Komiya Kazutoshi, Narisawa Yutaka, Kimura Shinya, Sueoka-Aragane Nao |
- Page last reviewed:Jul 25, 2022
- Page last updated:Jan 27, 2023
- Content source: